Six studies focusing on clinical practice
At NLC 2026, Chiesi was proud to have contributed to results from 6 different studies focusing on four clinically meaningful themes: better identification of patients with unmet need on their current treatment regimen, more effective escalation to fixed triple therapy, improved adherence and inhaler technique, and reduced exacerbation burden across asthma and COPD.
Here is a selection of our contributions
A Delphi consensus on interpretations of oscillometry
POSTER
Presented by Ingvild Bjellmo Johnsen
Interpreting respiratory oscillometry in adults with asthma or COPD: findings from an international Delphi study.
An international Delphi study generated expert consensus on how to interpret respiratory oscillometry in adults with asthma or COPD. Using a limited set of key parameters (R5, X5 and AX) for identifying abnormal lung function, bronchodilator response and clinically meaningful change was recommended. This expert consensus outlines how advanced physiological assessment can complement routine routine lung function evaluation in everyday care by early identification of small airways dysfunction and improved assessment of treatment response in both asthma and COPD.
Chung et al. Interpreting respiratory oscillometry in adults with asthma or COPD: findings from an international Delphi study. Nordic Lung Congress 2026, Reykjavik, Island, June 2026.
Can digital tools help improve asthma control by improving adherence and technique?
POSTER
Presenting author: Charlotte Suppli Ulrik
Effect of a Smart Inhaler Add-On on Adherence and Inhaler Technique in Patients with Poorly Controlled Asthma Concise summary.
This protocol describes a 52-week observational study evaluating whether the SiA®SMARTer digital platform can improve adherence and inhaler technique in adults with poorly controlled asthma receiving single-inhaler triple therapy, while also helping distinguish poor control due to non-adherence or incorrect technique from poor control requiring treatment escalation.
This study addresses a major real-world challenge in asthma management: whether poor outcomes reflect insufficient treatment intensity or suboptimal medication use. The study therefore links digital support, technique optimisation and more precise escalation decisions.
Bækdal et al. Study protocol: Effect of a Smart Inhaler Add-On on Adherence and Inhaler Technique in Patients with Poorly Controlled Asthma Concise summary. Nordic Lung Congress 2026, Reykjavik, Island, June 2026.
Asthma escalation practice differs within Europe
POSTER
LAMA Use in Asthma Management: Insights from the EU-LAMA Study with a Focus on Sweden
The EU-LAMA survey shows that Swedish physicians use triple therapy and prescribe fixed triple inhalers in asthma less often than the overall European sample, more often favour LTRA, and cite lack of clear guideline recommendations as the main barrier to greater LAMA use.
This poster is relevant because it identifies a clear implementation gap in asthma escalation practice—especially around LAMA and fixed triple use—and highlights where further clinical education, evidence translation and discussion of guideline-aligned treatment pathways may be needed.
Janson et al. LAMA Use in Asthma Management: Insights from the EU-LAMA Study with a Focus on Sweden. Nordic Lung Congress 2026, Reykjavik, Island, June 2026.
Clinical decisions vary despite similar disease severity
ORAL PRESENTATION
Lowie Vanfleteren
Prescription of pharmacotherapy for COPD in Sweden diverts from the expected in groups stratified by disease severity and sex.
In Sweden, COPD pharmacotherapy broadly reflects symptoms and exacerbation history, but prescriptions still vary within patient groups of similar severity, according to national registry data. Additional differences were seen between men and women, indicating a gap between guideline recommendations and everyday clinical practice. Men were more often untreated, and women were more often prescribed triple treatment in multiple inhalers.
Implementation of guideline-based treatment in real-world prescribing is a core issue in COPD. Understanding current gaps may benefit a systematic approach for individualised treatment decisions and optimisation of inhaled therapy in routine practice.
Vanfleteren et al. Prescription of pharmacotherapy for COPD in Sweden diverts from the expected in groups stratified by disease severity and sex. Nordic Lung Congress 2026, Reykjavik, Island, June 2026.
ID22693-22.06.2026